Cardiothoracic Surgery Center for Clinical Research

CT surgery clinical researchThe Cardiothoracic Surgery Center for Clinical Research (CCR) of the Emory University School of Medicine conducts high-impact clinical and translational research and develops and investigates new techniques and technologies in cardiothoracic surgery to inform evidence-based practice.

Cardiothoracic surgeon scientist Dr. John Puskas founded the Emory CCR in 2005. Dr. Puskas was an early advocate of off-pump CT surgery, and had an important role in validating such procedures as off-pump coronary artery bypass surgery. With an impressive cadre of faculty investigators and robust staff support, he developed the CCR into a highly active research center. Dr. Puskas left Emory in March 2014 to join Mount Sinai Beth Israel Hospital, and Dr. Michael Halkos took over as the CCR's scientific director.

As a member of the Cardiothoracic Surgical Trials Network (CTSN), a consortium of adult cardiac surgery centers supported by the NIH's National Heart, Lung, and Blood Institute, the CCR participates in multi-institutional prospective randomized trials that evaluate new surgical methods, technologies, devices, and innovative pharmaceutical and bioengineered products.

The CCR has served as the national or international PI site for several FDA IDE trials, ranging from innovative transcatheter aortic valve replacements to reduced anticoagulation for mechanical heart valves. CCR scientists have also conducted landmark, investigator-initiated, randomized controlled trials in stroke prevention, endoscopic vein harvest, and off-pump coronary artery bypass grafting, and have enrolled patients in many multicenter clinical trials in cardiac and thoracic surgery.


Investigators

Dr. Michael Halkos

SCIENTIFIC DIRECTOR: Michael E. Halkos, MD, MSc

Dr. Halkos is the current chief of the Emory Division of Cardiothoracic Surgery. He is a highly experienced and productive academic cardiac surgeon-scientist with expertise in minimally invasive cardiac surgery, particularly robotic mitral valve surgery, robotic-assisted coronary artery bypass surgery, hybrid coronary revascularization, hybrid atrial fibrillation ablation, and mitral valve repair techniques. Together with Douglas Murphy, MD, at Emory Saint Joseph's Hospital, he leads one of the largest and most successful robotic cardiac surgical programs in the world.

As an accomplished researcher, Dr. Halkos is considered one of the world's leading experts in robotic cardiac surgery, and has published extensively on robotic approaches to mitral valve surgery, mitral valve repair, coronary artery bypass grafting, and hybrid coronary revascularization. He was the Department of Surgery's first faculty member to receive an NHLBI K-23 Award, received his Master's Degree in Clinical Research in 2012, and currently serves as principal investigator for multiple industry- and NIH-sponsored trials.

Dr. Robert Guyton

Robert A. Guyton, MD

Dr. Guyton served as chief of the Emory Division of Cardiothoracic Surgery from 1990-2017. During his time at Emory he has been involved in the creation and refinement of numerous cardiothoracic surgical techniques. Beginning in 2007, he joined Emory CT surgeon scientist Dr. Vinod Thourani and Emory cardiologists Dr. Vasilis Babaliaros and Dr. Peter Block as one of the local surgical co-PIS  of the multi-center PARTNER I trial of transcatheter aortic valve replacement (TAVR). The results of the national trial influenced FDA approval of the SAPIEN transfemoral transcatheter heart valve in 2011.

In 2014, Dr. Guyton was inducted into Emory's Millipub Club for being co-author of a paper that has been cited more than 1,000 times in the literature: "Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery," published in the October 2010 edition of New England Journal of Medicine. The paper reported the results of comparing TAVR to such standard therapies as balloon aortic valvuloplasty, and concluded that the reduced mortality among patients treated with TAVR as opposed to traditional methods was significant.

Dr. Guyton is also the director of the Emory Cardiothoracic Research Lab (CTRL).

Dr. Omar Lattouf

Omar M. Lattouf, MD, PhD

Dr. Lattouf has extensive experience in complex cardiac procedures including heart transplantation, laser re-vascularization, left ventricular reduction procedures, thoracoscopic minimally invasive interventional therapy, and Alfieri mitral repair. In addition to having numerous patents, Dr. Lattouf has various patents pending and is involved in developing a variety of cardiac surgery-associated methods and devices for patent consideration.

Dr. Lattouf's research focuses on complex coronary revascularization utilizing off-pump vs. on-pump techniques, transmyocardial laser revascularization to improve myocardial perfusion and reduction of angina, the role of stem cells in treating end-stage ischemic or idiopathic cardiomyopathy, and the diagnosis and treatment of heparin induced thrombocytopenia.

Dr. Bradley G. Leshnower

Bradley G. Leshnower, MD

Dr. Leshnower's research interests include diseases of the thoracic aorta, clinical studies of patient outcomes following medical and surgical treatment of aneurysmal disease and aortic dissection, and basic science investigations of the pathophysiology of acute and chronic aortic dissection. In 2016, he was the first recipient of the Thoracic Surgery Foundation (TSF)/Southern Thoracic Surgical Association (STSA) Research Grant, which is funding his pilot study to determine the optimal cerebral protection strategy during aortic arch replacement.

Dr. J. David Vega

J. David Vega, MD

Dr. Vega is the surgical director of the ventricular assist device (VAD) and heart transplant programs at Emory. His primary research has evaluated the use of mechanical circulatory support devices as a bridge to transplant or for destination therapy.

In 2006, Dr. Vega was the first physician in Georgia to implant a VAD as a form of destination therapy in a patient who was ineligible for or are unwilling to undergo a heart transplant. In 2007, he was the first Georgia surgeon to implant an even smaller VAD for the same purpose. Emory's VAD destination therapy program now has the "Gold Seal of Approval" from The Joint Commission, and is one of only two certified programs of its kind in Georgia and one of approximately 80 centers in the U.S.

««return to top